Mass screening for the short-term effects of nimotuzumab combined with synchronal radiochemotherapy in the treatment of locally advanced esophageal carcinoma
Dandan Huang,Tao Li,Jun Zhang,Bo Chen,Jinyi Lang
DOI: https://doi.org/10.3969/j.issn.1000-8179.2012.23.023
2012-01-01
Chinese Journal of Clinical Oncology
Abstract:Objective: To evaluate the short-term, adverse effects of nimotuzumab combined with synchronal radio-chemotherapy in the treatment of locally advanced esophageal carcinoma. Methods: Sixty-five patients, treated in our hospital from January 2010 to January 2011, with inoperable, locally advanced esophageal cancer, were divided into three groups. In the radiotherapy group, 14 patients were treated with radiotherapy alone. Intensity-modulated radiotherapy (IMRT) was conducted, with fractional doses of 1.8 Gy/F to 2.2 Gy/F, five times a week with an overall treatment time of six to nine weeks, and a total dose of 50 Gy to 66 Gy. In the synchronal radio-chemotherapy group, 29 patients were treated with radiotherapy and chemotherapy, using the same radiotherapy regimen as in the radiotherapy group. In addition, the patients were also treated with the TP scheme for two to four cycles, and radiotherapy and chemotherapy were conducted simultaneously. In the group with nimotuzumab combined with synchronal radio-chemotherapy, 22 patients were treated with the same radiotherapy and chemotherapy regimen as in the synchronal radio-chemotherapy group. In addition, the patients were administered 200 mg of nimotuzumab per week, for a total of six to nine times. Short-term adverse effects were monitored. Results: Among the 65 patients, complete remission (CR) was seen in 7, partial remission (PR) in 46, stable disease (SD) in 8, and progressive development (PD) in 4; the total response rate was 81.5%. In Group A (radiotherapy group), PR was found in 8 cases, SD in 4, and PD in 2; the total response rate was 57.1%. In Group B (synchronal radio-chemotherapy), CR was found in 3 cases, PR in 22, SD in 2, and PD in 2; the total response rate was 86.2%. In Group C (nimotuzumab combined with synchronal radio-chemotherapy), CR was found in 4 cases, PR in 16, and NC in 2; the total response rate was 90.9%, and only 2 patients (9.1%) developed a skin rash (grade I), 1 patient (4.5%) experienced nausea (grade I), 2 patients (9.1%) exhibited a mild lowering of blood pressure, but recovered without treatment. Treatment was not affected in any of these cases. Conclusion: The short-term response rates of patients with locally advanced esophageal carcinoma in Groups B and C are higher than those in Group A. However, whether treatment with nimotuzumab combined with synchronal radio-chemotherapy is more effective than treatment with synchronal radiochemotherapy is uncertain. Nimotuzumab, which has mild side effects, is tolerated well. As the sample size in this study is small, validation using a larger sample size is needed.